Andere Sprachen Adial Pharmaceuticals, Inc.

Aktien

A3ERJP

US00688A2050

ADIL

Verzögert Nasdaq Andere Börsenplätze 19:30:00 03.07.2024			% 5 Tage	% 1. Jan.
1.045 ^USD	+0.48%		-5.00%	-43.82%

05.06.	Adial Pharmaceuticals, Inc. erreicht wichtigen Meilenstein mit der Verabreichung des ersten Patienten in der Pharmakokinetikstudie von AD04 zur Behandlung von Alkoholproblemen	CI
14.05.	Adial Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder	20.06.
Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder	05.06.
Adial Pharmaceuticals, Inc. Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder	05.06.
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th	29.05.
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	15.05.
Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder	22.04.
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office	22.04.
Top Premarket Decliners	12.04.
Top Midday Gainers	10.04.
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder	10.04.
Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder	10.04.
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update	02.04.
Adial Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Adial Pharmaceuticals, Inc. announced that it has received $0.2875 million in funding	14.03.
Adial Pharmaceuticals, Inc. announced that it expects to receive $0.2875 million in funding	06.03.
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds	04.03.
Top Premarket Decliners	04.03.
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds	02.03.
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	01.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Adial Pharmaceuticals, Inc.

Aktien

A3ERJP

US00688A2050

ADIL

Andere Sprachen

Filter